当前位置:科学网首页 > 小柯机器人 >详情
抗HIV-1抗体联用疗法与病毒特异性T细胞免疫增加相关
作者:小柯机器人 发布时间:2020/2/4 10:54:19

加拿大蒙特利尔大学Daniel E. Kaufmann、美国洛克菲勒大学Michel C. Nussenzweig等研究人员合作发现,抗HIV-1抗体联用疗法与病毒特异性T细胞免疫增加相关。2020年2月3日,《自然—医学》在线发表了这项成果。

具研究人员介绍,联合抗逆转录病毒疗法(ART)在控制人类免疫缺陷病毒(HIV)-1方面非常有效,但由于存在潜伏的病毒库,因此需要终身服药。强效的广泛中和抗体(bNAb)可作为ART的潜在替代品或佐剂。除抑制病毒血症外,bNAb可能还具有T细胞免疫调节作用,正如在其他形式的免疫疗法中看到的。但是,尚未在感染HIV-1的个体中确定这一点。
 
研究人员发现,在接受ART中断期间接受bNAb治疗的所有9名患者(感染了HIV-1并具有抑制的血液病毒血症)的外周血中,HIV-1 Gag特异性CD8+T细胞应答的增加。在八个人中检测到增加的CD4+T细胞反应。T细胞反应的增加是由于对HIV-1 Gag表位的可检测反应性以及已存在的可测量反应的扩大。这些数据表明,ART中断期间的bNAb治疗与HIV-1特异性T细胞应答增强有关。这些增强的T细胞反应是否可以促进bNAb介导的病毒控制尚待确定。
 
附:英文原文

Title: Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity

Author: Julia Niessl, Amy E. Baxter, Pilar Mendoza, Mila Jankovic, Yehuda Z. Cohen, Allison L. Butler, Ching-Lan Lu, Mathieu Dub, Irina Shimeliovich, Henning Gruell, Florian Klein, Marina Caskey, Michel C. Nussenzweig, Daniel E. Kaufmann

Issue&Volume: 2020-02-03

Abstract: Combination antiretroviral therapy (ART) is highly effective in controlling human immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a latent viral reservoir1,2. Potent broadly neutralizing antibodies (bNAbs) represent a potential alternative or adjuvant to ART. In addition to suppressing viremia, bNAbs may have T cell immunomodulatory effects as seen for other forms of immunotherapy3. However, this has not been established in individuals who are infected with HIV-1. Here, we document increased HIV-1 Gag-specific CD8+ T cell responses in the peripheral blood of all nine study participants who were infected with HIV-1 with suppressed blood viremia, while receiving bNAb therapy during ART interruption4. Increased CD4+ T cell responses were detected in eight individuals. The increased T cell responses were due both to newly detectable reactivity to HIV-1 Gag epitopes and the expansion of pre-existing measurable responses. These data demonstrate that bNAb therapy during ART interruption is associated with enhanced HIV-1-specific T cell responses. Whether these augmented T cell responses can contribute to bNAb-mediated viral control remains to be determined.

DOI: 10.1038/s41591-019-0747-1

Source: https://www.nature.com/articles/s41591-019-0747-1

期刊信息

Nature Medicine:《自然—医学》,创刊于1995年。隶属于施普林格·自然出版集团,最新IF:30.641
官方网址:https://www.nature.com/nm/
投稿链接:https://mts-nmed.nature.com/cgi-bin/main.plex